vs
OPPENHEIMER HOLDINGS INC（OPY）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是OPPENHEIMER HOLDINGS INC的1.3倍（$622.0M vs $472.6M），Royalty Pharma plc净利率更高（34.4% vs 15.7%，领先18.7%），OPPENHEIMER HOLDINGS INC同比增速更快（25.9% vs 4.8%），过去两年OPPENHEIMER HOLDINGS INC的营收复合增速更高（15.7% vs 4.6%）
奥本海默控股是一家美国跨国独立投资银行与金融服务企业，面向全球客户提供投资银行、财务咨询、资本市场、资产管理及财富管理等相关产品与服务，目前总部设于纽约市宽街85号。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
OPY vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.3倍
$472.6M
营收增速更快
OPY
高出21.1%
4.8%
净利率更高
RPRX
高出18.7%
15.7%
两年增速更快
OPY
近两年复合增速
4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $472.6M | $622.0M |
| 净利润 | $74.4M | $214.2M |
| 毛利率 | — | — |
| 营业利润率 | 22.4% | 62.4% |
| 净利率 | 15.7% | 34.4% |
| 营收同比 | 25.9% | 4.8% |
| 净利润同比 | 593.1% | 2.9% |
| 每股收益（稀释后） | $6.51 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OPYRPRX
| Q4 25 | $472.6M | $622.0M | ||
| Q3 25 | $424.4M | $609.3M | ||
| Q2 25 | $373.2M | $578.7M | ||
| Q1 25 | $367.8M | $568.2M | ||
| Q4 24 | $375.4M | $593.6M | ||
| Q3 24 | $373.4M | $564.7M | ||
| Q2 24 | $330.6M | $537.3M | ||
| Q1 24 | $353.1M | $568.0M |
净利润OPYRPRX
| Q4 25 | $74.4M | $214.2M | ||
| Q3 25 | $21.7M | $288.2M | ||
| Q2 25 | $21.7M | $30.2M | ||
| Q1 25 | $30.7M | $238.3M | ||
| Q4 24 | $10.7M | $208.2M | ||
| Q3 24 | $24.5M | $544.0M | ||
| Q2 24 | $10.3M | $102.0M | ||
| Q1 24 | $26.1M | $4.8M |
营业利润率OPYRPRX
| Q4 25 | 22.4% | 62.4% | ||
| Q3 25 | 7.5% | 70.1% | ||
| Q2 25 | 8.6% | 36.3% | ||
| Q1 25 | 11.2% | 94.0% | ||
| Q4 24 | 4.5% | 60.9% | ||
| Q3 24 | 9.5% | — | ||
| Q2 24 | 4.8% | 50.2% | ||
| Q1 24 | 10.6% | -13.0% |
净利率OPYRPRX
| Q4 25 | 15.7% | 34.4% | ||
| Q3 25 | 5.1% | 47.3% | ||
| Q2 25 | 5.8% | 5.2% | ||
| Q1 25 | 8.3% | 41.9% | ||
| Q4 24 | 2.9% | 35.1% | ||
| Q3 24 | 6.6% | 96.3% | ||
| Q2 24 | 3.1% | 19.0% | ||
| Q1 24 | 7.4% | 0.8% |
每股收益（稀释后）OPYRPRX
| Q4 25 | $6.51 | $0.49 | ||
| Q3 25 | $1.90 | $0.67 | ||
| Q2 25 | $1.91 | $0.07 | ||
| Q1 25 | $2.72 | $0.55 | ||
| Q4 24 | $0.92 | $0.46 | ||
| Q3 24 | $2.16 | $1.21 | ||
| Q2 24 | $0.92 | $0.23 | ||
| Q1 24 | $2.37 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $38.4M | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $983.8M | $9.7B |
| 总资产 | $3.7B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资OPYRPRX
| Q4 25 | $38.4M | $618.7M | ||
| Q3 25 | $38.3M | $938.9M | ||
| Q2 25 | $37.6M | $631.9M | ||
| Q1 25 | $36.7M | $1.1B | ||
| Q4 24 | $33.1M | $929.0M | ||
| Q3 24 | $32.2M | $950.1M | ||
| Q2 24 | $33.2M | $1.8B | ||
| Q1 24 | $27.7M | $843.0M |
总债务OPYRPRX
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | $0 | $7.6B | ||
| Q3 24 | $112.8M | $7.6B | ||
| Q2 24 | $112.8M | $7.6B | ||
| Q1 24 | $112.7M | $6.1B |
股东权益OPYRPRX
| Q4 25 | $983.8M | $9.7B | ||
| Q3 25 | $920.3M | $9.6B | ||
| Q2 25 | $896.9M | $9.5B | ||
| Q1 25 | $872.3M | $9.8B | ||
| Q4 24 | $850.4M | $10.3B | ||
| Q3 24 | $837.8M | $10.3B | ||
| Q2 24 | $812.1M | $9.8B | ||
| Q1 24 | $801.5M | $9.9B |
总资产OPYRPRX
| Q4 25 | $3.7B | $19.6B | ||
| Q3 25 | $3.8B | $19.3B | ||
| Q2 25 | $3.7B | $18.3B | ||
| Q1 25 | $3.6B | $17.6B | ||
| Q4 24 | $3.4B | $18.2B | ||
| Q3 24 | $3.4B | $18.0B | ||
| Q2 24 | $3.3B | $17.7B | ||
| Q1 24 | $3.3B | $16.1B |
负债/权益比OPYRPRX
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | 0.00× | 0.74× | ||
| Q3 24 | 0.13× | 0.74× | ||
| Q2 24 | 0.14× | 0.78× | ||
| Q1 24 | 0.14× | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $188.8M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $183.6M | — |
| 自由现金流率自由现金流/营收 | 38.8% | — |
| 资本支出强度资本支出/营收 | 1.1% | — |
| 现金转化率经营现金流/净利润 | 2.54× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $191.3M | — |
8季度趋势，按日历期对齐
经营现金流OPYRPRX
| Q4 25 | $188.8M | $827.1M | ||
| Q3 25 | $63.4M | $702.6M | ||
| Q2 25 | $40.1M | $364.0M | ||
| Q1 25 | $-91.7M | $596.1M | ||
| Q4 24 | $-108.2M | $742.5M | ||
| Q3 24 | $11.4M | $703.6M | ||
| Q2 24 | $-115.3M | $658.2M | ||
| Q1 24 | $-79.0M | $664.6M |
自由现金流OPYRPRX
| Q4 25 | $183.6M | — | ||
| Q3 25 | $62.2M | — | ||
| Q2 25 | $38.9M | — | ||
| Q1 25 | $-93.4M | — | ||
| Q4 24 | $-113.3M | — | ||
| Q3 24 | $11.2M | — | ||
| Q2 24 | $-116.7M | — | ||
| Q1 24 | $-79.3M | — |
自由现金流率OPYRPRX
| Q4 25 | 38.8% | — | ||
| Q3 25 | 14.7% | — | ||
| Q2 25 | 10.4% | — | ||
| Q1 25 | -25.4% | — | ||
| Q4 24 | -30.2% | — | ||
| Q3 24 | 3.0% | — | ||
| Q2 24 | -35.3% | — | ||
| Q1 24 | -22.5% | — |
资本支出强度OPYRPRX
| Q4 25 | 1.1% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 0.3% | — | ||
| Q1 25 | 0.5% | — | ||
| Q4 24 | 1.4% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.1% | — |
现金转化率OPYRPRX
| Q4 25 | 2.54× | 3.86× | ||
| Q3 25 | 2.92× | 2.44× | ||
| Q2 25 | 1.85× | 12.06× | ||
| Q1 25 | -2.99× | 2.50× | ||
| Q4 24 | -10.08× | 3.57× | ||
| Q3 24 | 0.47× | 1.29× | ||
| Q2 24 | -11.23× | 6.45× | ||
| Q1 24 | -3.03× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OPY
| Advisory Fees | $166.6M | 35% |
| Capital Markets Segment | $155.5M | 33% |
| Other | $57.2M | 12% |
| Commissions From Sales And Trading | $52.9M | 11% |
| Bank Deposit Sweep Income | $27.7M | 6% |
| Mutual Fund Income | $8.9M | 2% |
| Investment Banking Capital Markets | $3.3M | 1% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
